GEOFFREY HSU

Geoffrey Hsu stands as a distinguished General Partner at OrbiMed, one of the world's largest and most influential healthcare-dedicated investment firms. With a career deeply rooted in the life sciences and finance, Mr. Hsu plays a critical role in shaping OrbiMed's investment strategies and portfolio across the global healthcare landscape. His extensive experience and profound understanding of the sector enable OrbiMed to identify and nurture groundbreaking companies that are poised to revolutionize patient care and medical innovation.

At OrbiMed, Geoffrey Hsu's investment focus is broad yet specialized, encompassing the full spectrum of the healthcare industry. This includes pioneering biopharmaceutical companies developing novel drugs, innovative medical device manufacturers creating next-generation tools, advanced diagnostics firms, and transformative healthcare services and digital health platforms. He is actively involved in investments spanning various stages, from early-stage venture capital opportunities that foster nascent technologies to growth equity investments supporting expanding companies, and public market investments in established leaders. This comprehensive approach allows OrbiMed to capture value across the entire lifecycle of healthcare innovation, from discovery to market leadership.

Mr. Hsu's journey in healthcare finance began long before his tenure as a General Partner. He joined OrbiMed in 2000, bringing with him a solid foundation in financial analysis and strategic insight. Prior to OrbiMed, he honed his expertise as an Analyst in the healthcare investment banking group at Goldman Sachs. This early experience provided him with invaluable exposure to the financial intricacies and strategic imperatives of the healthcare sector, preparing him for a leadership role in investment. Academically, Mr. Hsu is an alumnus of Harvard University, where he earned his B.A., further solidifying his analytical and intellectual capabilities.

OrbiMed, under the guidance of partners like Geoffrey Hsu, is renowned for its commitment to backing companies that address significant unmet medical needs and improve global health outcomes. The firm's investment philosophy emphasizes rigorous scientific and clinical due diligence, combined with a deep understanding of market dynamics and regulatory pathways. While specific individual investments are often part of a broader team effort, Mr. Hsu's leadership contributes significantly to OrbiMed's track record of successful investments in companies that have brought life-changing therapies and technologies to patients worldwide. His strategic vision helps drive OrbiMed's mission to invest in the future of healthcare, fostering innovation and delivering strong returns for its investors.